Pharmacokinetics of single and multiple infusions of 5S intravenous immunoglobulin.
A prospective, open and uncontrolled trial was performed to investigate the pharmacokinetics of a 5S intravenous immunoglobulin (IVIG) after single and multiple infusions. Twelve healthy volunteers received a 5S-IVIG enriched in antibodies against Staphylococcus aureus alpha-toxin (aSAT) either as a single infusion or as three infusions in daily intervals. The fate of the injected immunoglobulin was observed by serial measurements of the serum level of aSAT titres. The 5S-IVIG had a half-life with a median of 0.24 (distribution) and 2.0 (terminal) days, respectively. The pharmacokinetic parameters did not differ with dose groups or number of applications. The study medication was well tolerated.
Theobald
K
K
Clinical Research Immunoregulation, SBU Therapeutics, Behringwerke AG, Marburg, Germany.
Högy
B
B
D000328:Adult; D000907:Antibodies, Bacterial; D001427:Bacterial Toxins / Q000276:immunology*; D006460:Hemolysin Proteins / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007262:Infusions, Intravenous; D008875:Middle Aged; D011446:Prospective Studies; D013211:Staphylococcus aureus
D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D006460:Hemolysin Proteins; D016756:Immunoglobulins, Intravenous; C021091:staphylococcal alpha-toxin